| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $20.9M | — | +60.1% |
| SG&A Expense | $6.4M | — | +22.2% |
| Operating Income | -$27.3M | — | -49.2% |
| Net Income | -$25.2M | — | -58.7% |
| EPS (Basic) | -$1.34 | — | -44.1% |
| EPS (Diluted) | -$1.34 | — | -44.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $236.9M | -6.7% | -22.6% |
| Current Assets | $239.9M | -6.8% | -22.5% |
| Total Assets | $246.6M | -5.5% | -21.7% |
| Current Liabilities | $13.0M | +34.1% | -4.1% |
| Total Liabilities | $16.2M | +66.4% | +17.2% |
| Stockholders' Equity | $230.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$18.4M | — | -40.7% |
| Capital Expenditures | $19K | — | -29.6% |
| Investing Cash Flow | -$19K | — | +29.6% |
| Financing Cash Flow | $847K | — | -99.5% |
| Free Cash Flow | -$18.4M | — | -40.6% |
| -23.5% |